motapizone has been researched along with tolafentrine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Enke, B; Ghofrani, HA; Grimminger, F; Schermuly, RT; Schudt, C; Seeger, W; Walmrath, D; Weissmann, N | 1 |
| Ghofrani, HA; Grimminger, F; Roehl, A; Schermuly, RT; Schudt, C; Seeger, W; Tenor, H; Walmrath, D; Weissmann, N | 1 |
2 other study(ies) available for motapizone and tolafentrine
| Article | Year |
|---|---|
Low-dose systemic phosphodiesterase inhibitors amplify the pulmonary vasodilatory response to inhaled prostacyclin in experimental pulmonary hypertension.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Administration, Inhalation; Aerosols; Animals; Antihypertensive Agents; Blood Pressure; Cardiac Output; Dose-Response Relationship, Drug; Drug Therapy, Combination; Epoprostenol; Hypertension, Pulmonary; Naphthyridines; Phosphodiesterase Inhibitors; Pulmonary Circulation; Purinones; Pyridazines; Rabbits; Rolipram; Vasoconstrictor Agents; Vasodilation | 1999 |
Subthreshold doses of specific phosphodiesterase type 3 and 4 inhibitors enhance the pulmonary vasodilatory response to nebulized prostacyclin with improvement in gas exchange.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Aerosols; Animals; Antihypertensive Agents; Cyclic AMP; Dose-Response Relationship, Drug; Drug Interactions; Edema; Epoprostenol; Female; Hemodynamics; Hypertension, Pulmonary; Lung; Male; Naphthyridines; Perfusion; Phosphodiesterase Inhibitors; Pyridazines; Rabbits; Rolipram; Time Factors; Vasoconstrictor Agents | 2000 |